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aneurysm just after labeled SMC seeding. Hypointense signal areas
were present up to 28 days after cell transplantation.
Perls stainingandﬂuorescenthistological analysis conﬁrmthepresenceof
iron-labeled cells in contact with the lumina at day 0. At longer times,
parallel to intima formation, labeledcellswereobservedwithin intimaand
media up to day28. Immunohistological studiesconﬁrmed thepresenceof
iron-labeled smooth muscle cells. High-ﬁeld ex vivoMR imaging (9.4 T)
showed a well-deﬁned hypointense signal layer in gradient-echo
sequences which correlates with histological Perls staining.
Conclusions: This study showed the potential of these magnetic
nanoparticles as a cell label for long-termMRI in vivo. Labeled cells are
easily detected even after 1 month. All data conﬁrmed the integration of
SMCwithin the aneurysm aortic wall, allowing intima development and
stabilization of aneurysm lesions.
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Rationale and Objectives: Anticancer immunotherapies using den-
dritic cells (DCs) are currently being explored in the clinic. For these
therapies, accurate delivery to target organs is essential. Correct delivery
and subsequent migration of vaccinated DCs to regional lymph nodes
(LNs) is of paramount importance for effective stimulation of the
immune system. Using magnetically labeled DCs, we investigated the
potential of magnetic resonance imaging (MRI) for cell tracking to
monitor DC therapy.
Methods: Autologous monocyte-derived DCs were labeled with the
clinically approved superparamagnetic iron oxide (SPIO) formulation
Endorem (Guerbet, Paris, France) and [111 In]oxine separately and co-
injected into the draining LNs of stage III melanoma patients (n¼ 8)
under ultrasound guidance. Two days after vaccination, patients were
monitored by scintigraphy and MRI at 3 T.
Results: We showed that in vivo MR tracking of magnetically labeled
cells is feasible in humans for detecting very low numbers of DCs in
conjunction with detailed anatomical information. In contrast to
scintigraphic imaging, MRI allowed the assessment of accurate DC
delivery and inter- and intra-nodal migration patterns. SPIO-labeled cells
were detected in the injected LN, but also in following LNs [e.g. see
Fig. 1(A)]. The LNs were then resected and monitored by MRI at 7 T
[Fig. 1(B)]. The presence of SPIO-labeled cells in theLNwas conﬁrmedby
histology of the resected nodes [Fig 1(C)]. Moreover, histochemistry
revealed that SPIO-labeled DC had migrated into the T-cell areas [Fig.
1(D)] of the injected and following LNs. SPIO-labeled cells in the T-cell
areawere still positive for theDCmaturationmarkerCD83andnegative for
the macrophage marker CD68 [Fig. 1(E)].
Conclusion: MRI cell tracking using iron oxides appears clinically
safe and extremely well suited to monitor cellular therapy in humans.
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[CMR 2005: 9.07] Figure 1. (A) MRI (3 T) of a patient injected with SPIO-labeled DC. Arrows indicate the injected LN (1) and one of four following
LNs (2) towhere SPIO-DC hadmigrated. (B)MRI (7 T) of resected lymph node 2 days after injection of SPIO-labeledDC. (C–E)Histology of sameLN
as in B. Blue, iron; red, nuclei. (D) Detail of the T cell area of an LN to which SPIO-labeled DC had migrated. (E) Immunohisotochemistry of SPIO-
labeled cells in T-cell area of LN. Brown, CD68; in inlet, CD83
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